1. Enhanced antiopiate activity in peptidomimetics of FMRFamide containing Z-2,3-methanomethionine
- Author
-
Linda S. Corriere, Kwok-Kan Ho, Kevin Burgess, David H. Malin, Roxanna S. Kelley, Kemal Payza, J.Ronald Lake, David A. Smith, and Tracey M. Benson
- Subjects
Male ,medicine.medical_specialty ,Physiology ,Peptidomimetic ,Molecular Sequence Data ,Neuropeptide ,Peptide ,In Vitro Techniques ,Biochemistry ,Rats, Sprague-Dawley ,Cellular and Molecular Neuroscience ,Methionine ,Endocrinology ,Internal medicine ,medicine ,Animals ,Amino Acid Sequence ,FMRFamide ,Neuropeptide FF ,Endorphins ,Receptor ,chemistry.chemical_classification ,Oligopeptide ,Molecular Structure ,Neuropeptides ,Rats ,Receptors, Neurotransmitter ,chemistry ,Morphine Dependence ,Oligopeptides - Abstract
FMRFa is a molluscan peptide that has shown antiopiate activity in a number of mammalian test systems. The current study determined the antiopiate potency of FMRFa and two conformationally constrained peptidomimetics of FMRFa containing stereoisomers of Z-2,3-methanomethionine. Morphine abstinence signs were observed after varying doses (0.25-25.0 micrograms) of these substances were injected into the third ventricle of morphine-dependent rats. Although both peptidomimetics were far more potent than FMRFa itself, they bound with lower affinity than FMRFa to rat spinal cord receptors for the mammalian FMRFa-like peptide, NPFF.
- Published
- 1993
- Full Text
- View/download PDF